alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5220 Blow bottle. ( a ) *Identification.* A blow bottle is a device that is intended for medical purposes to induce a forced expiration from a patient. The patient blows into the device to move a column of water from one bottle to another.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9. If the device is not labeled or otherwise represented as sterile, it is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[47 FR 31142, July 16, 1982, as amended at 54 FR 25048, June 12, 1989; 66 FR 38794, July 25, 2001]
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Pages 10243-10244]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4608]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EL09-40-001]


Southwest Power Pool, Inc.; Notice of Filing

February 25, 2010.
    Take notice that on February 22, 2010, Southwest Power Pool, Inc. 
filed a revision to its Open Access Transmission Tariff to conform the 
matching requirement in its Tariff provisions allowing incumbent 
transmission customers to renew, or ``rollover,'' Their contracts for 
transmission service to the matching requirement of the Commission's 
pro forma OATT, to be effective January 21, 2010, in compliance with 
the Commission's January 21, 2010 order, Sw. Power Pool, Inc., 130 FERC 
] 61,049 (2010) (January 21 Order).
    Any person desiring to intervene or to protest this filing must 
file in

[[Page 10244]]

accordance with Rules 211 and 214 of the Commission's Rules of Practice 
and Procedure (18 CFR 385.211, 385.214). Protests will be considered by 
the Commission in determining the appropriate action to be taken, but 
will not serve to make protestants parties to the proceeding. Any 
person wishing to become a party must file a notice of intervention or 
motion to intervene, as appropriate. Such notices, motions, or protests 
must be filed on or before the comment date. Anyone filing a motion to 
intervene or protest must serve a copy of that document on the 
Applicant and all the parties in this proceeding.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov. Persons unable to file electronically should submit an 
original and 14 copies of the protest or intervention to the Federal 
Energy Regulatory Commission, 888 First Street, NE., Washington, DC 
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the 
``eLibrary'' link and is available for review in the Commission's 
Public Reference Room in Washington, DC. There is an ``eSubscription'' 
link on the Web site that enables subscribers to receive e-mail 
notification when a document is added to a subscribed docket(s). For 
assistance with any FERC Online service, please e-mail 
<a href="/cdn-cgi/l/email-protection#a4e2e1f6e7ebcac8cdcac1f7d1d4d4cbd6d0e4c2c1d6c78ac3cbd2"><span class="__cf_email__" data-cfemail="2c6a697e6f6342404542497f595c5c435e586c4a495e4f024b435a">[email protected]</span></a>, or call (866) 208-3676 (toll free). For 
TTY, call (202) 502-8659.
    Comment Date: 5 p.m. Eastern Time on March 15, 2010.

Kimberly D. Bose,
Secretary.
[FR Doc. 2010-4608 Filed 3-4-10; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                           6,459
<SECURITIES>                                    49,633
<RECEIVABLES>                                    2,523
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                60,543
<PP&E>                                          14,914
<DEPRECIATION>                                 (4,924)
<TOTAL-ASSETS>                                  74,283
<CURRENT-LIABILITIES>                           18,339
<BONDS>                                         12,478
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            15
<OTHER-SE>                                      43,466
<TOTAL-LIABILITY-AND-EQUITY>                    74,283
<SALES>                                              0
<TOTAL-REVENUES>                                 9,154
<CGS>                                                0
<TOTAL-COSTS>                                   32,020
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 392
<INCOME-PRETAX>                               (21,391)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (21,391)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (21,391)
<EPS-BASIC>                                     (1.88)
<EPS-DILUTED>                                   (1.88)


</TABLE>
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5910 Quality control material for cystic fibrosis nucleic acid assays. ( a ) *Identification.* Quality control material for cystic fibrosis nucleic acid assays. A quality control material for cystic fibrosis nucleic acid assays is a device intended to help monitor reliability of a test system by detecting analytical deviations such as those that may arise from reagent or instrument variation in genetic testing. This type of device includes recombinant, synthetic, and cell line-based DNA controls.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9. The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Quality Control Material for Cystic Fibrosis Nucleic Acid Assays.” See § 866.1(e) for the availability of this guidance document.
[72 FR 1176, Jan. 10, 2007, as amended at 84 FR 71811, Dec. 30, 2019]
<PAGE>

                                                              Exhibit 14.1

                     [Letterhead of BDO McCabe Lo & Company]

            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Deswell Industries, Inc.

We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (File Nos. 33-97162, 333-07946 and 333-110236) of Deswell
Industries, Inc. (the "Company") of our report dated June 16, 2004 relating to
the consolidated financial statements, appearing in the Company's Annual Report
on Form 20-F for the year ended March 31, 2004.

                                                     /s/ BDO McCabe Lo & Company
Hong Kong, July 16, 2004                             BDO McCabe Lo & Company
<PAGE>

                                                                    Exhibit 23.1

                       CONSENT OF INDEPENDENT ACCOUNTANTS

         We hereby consent to the incorporation by reference in the Registration
Statement on Form S-8 (No. 333-53374) of Evergreen Solar, Inc. of our report
dated February 27, 2003, except as to Note 13, for which the date is March 21,
2003 relating to the financial statements and financial statement schedule of
Evergreen Solar, Inc. included in this Form 10-K. We also consent to the
reference to us under the heading "Selected Financial Data" in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
-------------------------------
PricewaterhouseCoopers LLP

Boston, Massachusetts

March 26, 2003
§ 814.84 Reports. ( a ) The holder of an approved PMA shall comply with the requirements of part 803 and with any other requirements applicable to the device by other regulations in this subchapter or by order approving the device.
( b ) Unless FDA specifies otherwise, any periodic report shall: ( 1 ) Identify changes described in § 814.39(a) and changes required to be reported to FDA under § 814.39(b).
( 2 ) Contain a summary and bibliography of the following information not previously submitted as part of the PMA: ( i ) Unpublished reports of data from any clinical investigations or nonclinical laboratory studies involving the device or related devices and known to or that reasonably should be known to the applicant.
( ii ) Reports in the scientific literature concerning the device and known to or that reasonably should be known to the applicant. If, after reviewing the summary and bibliography, FDA concludes that the agency needs a copy of the unpublished or published reports, FDA will notify the applicant that copies of such reports shall be submitted.
( 3 ) Identify changes made pursuant to an exception or alternative granted under § 801.128 or § 809.11 of this chapter.
( 4 ) Identify each device identifier currently in use for the device, and each device identifier for the device that has been discontinued since the previous periodic report. It is not necessary to identify any device identifier discontinued prior to December 23, 2013.
[51 FR 26364, July 22, 1986, as amended at 51 FR 43344, Dec. 2, 1986; 67 FR 9587, Mar. 4, 2002; 72 FR 73602, Dec. 28, 2007; 78 FR 58822, Sept. 24, 2013]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1425 Programmable diagnostic computer. ( a ) *Identification.* A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.
( b ) *Classification.* Class II (performance standards).
_______________________________________ __ Michigan Supreme Court 

# Order

Lansing, Michigan



### September 10, 2007 Clifford W. Taylor, Chief Justice


### 134023 Michael F. Cavanagh Elizabeth A. Weaver Marilyn Kelly Maura D. Corrigan 

### PEOPLE OF THE STATE OF MICHIGAN, Plaintiff-Appellee, Robert P. Young, Jr. Stephen J. Markman, Justices



### v SC: 134023 COA: 276490 Oakland CC: 2005-205564-FC ANGEL HERIBERTO LUGO, Defendant-Appellant.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the April 4, 2007 order of the Court of Appeals is considered, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.

p0830 I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

September 10, 2007

Clerk
Court of Appeals

of the State of Georgia

ATLANTA,____________________

The Court of Appeals hereby passes the following order:

A18A0926. BROWN v. ROCK CREEK HOMEOWNER’S ASSOCIATION,

INC.

The appeal of the above-referenced case was docketed on December 12, 2017,

and the appellant was notified that his enumerations of error and brief were due

within 20 days of docketing (i.e., by January 2, 2018). Appellant filed a Motion for

Extension on January 2, 2018, requesting a twenty-day extension and was granted the

same until January 22, 2018. Appellant filed a second Motion for Extension on

January 19, 2018, requesting a ten-day extension and was again granted an extension

until February 1, 2018. Appellant has failed to file a brief as ordered by this Court.

Thus, this appeal is DISMISSED.

Court of Appeals of the State of Georgia

Clerk’s Office, Atlanta,____________________

I certify that the above is a true extract from

the minutes of the Court of Appeals of Georgia.

Witness my signature and the seal of said court

hereto affixed the day and year last above written.

, Clerk.

April 16, 2018

04/16/2018
### NUMBER 13

- 1 2

- 00 133

- CV



## COURT OF APPEALS

THIRTEENTH DISTRICT OF TEXAS

CORPUS CHRISTI

- EDINBURG

____________________________________________________________

JOSEPH BURT AND MARCO PIZANA

, A ppellant s

,

v.

ANNETTE CERDA AND BELIA CERDA

, A ppellee s

.

____________________________________________________________

On a ppeal from the 275th District Court

of Hidalgo County, Texas.

____________________________________________________________



## MEMORANDUM OPINION

Before Chief Justice Valdez an d Justices Garza and Longoria

Memorandum Opinion Per Curiam

The appellant s ’ brief in the above cause was due on October 3 , 2014 . On October

8 , 2014 , the Clerk of the Court notified appellant that the brief had not been timely filed

and that the appeal was subject to dismissal for want of prosecution under Texas Rule of

Appellate Procedure 38.8(a)(1), unless within ten days from the date of receipt of this

letter, appellant s reasonably explained the failure and the appellee s w ere not significantly2

injured by the appellant s ’ failure to timely file a brief. To date, no response has been

received from appellant s

.

Appellant s ha ve failed to either reasonably explain their failure to file a brief, file a

motion for extension of time to file the brief, or file the brief. Accordingly, the appeal is

DISMISSED FOR WANT OF PROSECUTION. See T EX

. R. A PP

. P . 38.8(a), 42.3(b).

PER CURIAM

D elivered and filed the

3 0 th day of October, 20 14

.
<TABLE> <S> <C>


<ARTICLE>                     5
                       
<MULTIPLIER>                  1
<CURRENCY>                    U.S. Dollars                
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               SEP-30-1999          
<PERIOD-START>                  OCT-01-1998    
<PERIOD-END>                    DEC-31-1998    
<EXCHANGE-RATE>                            1    
<CASH>                               143,579   
<SECURITIES>                               0    
<RECEIVABLES>                         14,400   
<ALLOWANCES>                               0   
<INVENTORY>                                0   
<CURRENT-ASSETS>                     157,979   
<PP&E>                               304,914   
<DEPRECIATION>                       126,526   
<TOTAL-ASSETS>                       336,367   
<CURRENT-LIABILITIES>                 29,348   
<BONDS>                                    0   
<PREFERRED-MANDATORY>                      0   
<PREFERRED>                                0   
<COMMON>                             122,146   
<OTHER-SE>                           154,801   
<TOTAL-LIABILITY-AND-EQUITY>         336,367   
<SALES>                                    0   
<TOTAL-REVENUES>                       3,000   
<CGS>                                      0   
<TOTAL-COSTS>                          9,458   
<OTHER-EXPENSES>                           0   
<LOSS-PROVISION>                           0   
<INTEREST-EXPENSE>                      (950)   
<INCOME-PRETAX>                       (5,508)       
<INCOME-TAX>                               0    
<INCOME-CONTINUING>                   (5,508)   
<DISCONTINUED>                             0    
<EXTRAORDINARY>                            0    
<CHANGES>                                  0    
<NET-INCOME>                          (5,508)    
<EPS-PRIMARY>                              0    
<EPS-DILUTED>                              0    
        


</TABLE>
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.8150 Calibrator for cell indices. ( a ) *Identification.* A calibrator for cell indices is a device that approximates whole blood or certain blood cells and that is used to set an instrument intended to measure mean cell volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC), or other cell indices. It is a suspension of particles or cells whose size, shape, concentration, and other characteristics have been precisely and accurately determined.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60631, Sept. 12, 1980, as amended at 84 FR 71800, Dec. 30, 2019]
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          APR-30-1998
<PERIOD-END>                               JAN-31-1998
<CASH>                                          20,298
<SECURITIES>                                         0
<RECEIVABLES>                                  606,685
<ALLOWANCES>                                         0
<INVENTORY>                                    108,958
<CURRENT-ASSETS>                             1,518,631
<PP&E>                                       6,115,605
<DEPRECIATION>                               1,159,981
<TOTAL-ASSETS>                               6,632,383
<CURRENT-LIABILITIES>                        1,650,853
<BONDS>                                      2,598,719
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    24,204,198
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 6,632,383
<SALES>                                              0
<TOTAL-REVENUES>                             2,018,459
<CGS>                                                0
<TOTAL-COSTS>                                  917,086
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             184,271
<INCOME-PRETAX>                              (695,108)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                237,500
<CHANGES>                                            0
<NET-INCOME>                                 (457,608)
<EPS-PRIMARY>                                    (.03)
<EPS-DILUTED>                                    (.03)
        

</TABLE>
EX-10.2(O)



 Exhibit 10.2(O) 

[OPTION AMENDMENT FOR OPTIONEES WHO REMAIN EMPLOYED BY ALTABA] 

[date] 
 [Full Name] 

Re: Amendment of Your Option Exercise Period 

Dear [First Name]: 
 This letter amends the award
agreements that govern your outstanding stock options (your “Options”) that were granted or assumed by Yahoo! Inc. (the “Company”) as described below. 

Your Options generally provide for a maximum term of seven years after the date of grant, subject to your continued employment with the
Company. However, following the closing of the transaction contemplated by the Company’s Stock Purchase Agreement with Verizon Communications Inc. (the “Closing”), applicable law will prohibit the Company from maintaining any
outstanding stock option awards (after a limited grace period). 
 Accordingly, effective as of the Closing, the award agreements evidencing
your Options are hereby amended to provide that your outstanding Options will remain exercisable in accordance with their terms for a period of up to ninety (90) days following the Closing (or, if earlier, until the expiration of the maximum
term of the Option) and, to the extent not exercised by the last day of such exercise period, will terminate at the close of business on such day. 

Except as expressly set forth above, this letter does not otherwise modify any other terms of your Option award agreements. If this letter
accurately sets forth our agreement with respect to the foregoing matters, please sign below and return a copy of this letter to me. 

Sincerely, 

YAHOO! INC. 

[Name] 

[Title] 
 Acknowledged and
Agreed: 

			
		
	By:	 	 
		 	[FULL NAME]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 7
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                              JAN-1-1997
<PERIOD-END>                               JUN-30-1997
<DEBT-HELD-FOR-SALE>                       252,133,844
<DEBT-CARRYING-VALUE>                                0
<DEBT-MARKET-VALUE>                                  0
<EQUITIES>                                  19,659,352
<MORTGAGE>                                           0
<REAL-ESTATE>                                        0
<TOTAL-INVEST>                             271,874,945
<CASH>                                      13,476,392
<RECOVER-REINSURE>                          10,524,465
<DEFERRED-ACQUISITION>                      98,951,344
<TOTAL-ASSETS>                             426,302,696
<POLICY-LOSSES>                            132,615,179
<UNEARNED-PREMIUMS>                              9,283
<POLICY-OTHER>                              62,263,501
<POLICY-HOLDER-FUNDS>                                0
<NOTES-PAYABLE>                             76,898,245
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       815,358
<OTHER-SE>                                 126,613,926
<TOTAL-LIABILITY-AND-EQUITY>               426,302,696
<PREMIUMS>                                  80,772,181
<INVESTMENT-INCOME>                          7,996,505
<INVESTMENT-GAINS>                             160,623
<OTHER-INCOME>                                 180,080
<BENEFITS>                                  56,887,015
<UNDERWRITING-AMORTIZATION>               (16,775,276)
<UNDERWRITING-OTHER>                        38,890,305
<INCOME-PRETAX>                             10,107,345
<INCOME-TAX>                                 2,957,838
<INCOME-CONTINUING>                          7,149,507
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 7,149,507
<EPS-PRIMARY>                                     0.95
<EPS-DILUTED>                                     0.86
<RESERVE-OPEN>                                       0
<PROVISION-CURRENT>                                  0
<PROVISION-PRIOR>                                    0
<PAYMENTS-CURRENT>                                   0
<PAYMENTS-PRIOR>                                     0
<RESERVE-CLOSE>                                      0
<CUMULATIVE-DEFICIENCY>                              0
        

</TABLE>